(MENAFN- GetNews)


"Exocrine Pancreatic Insufficiency Market Report 2034"Exocrine Pancreatic Insufficiency companies are AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Orlando Health, Inc., Chiesi Farmaceutici, and others.

DelveInsight's“Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast–2034” provides a comprehensive analysis of Exocrine Pancreatic Insufficiency (EPI), covering historical and projected epidemiological trends, as well as current and future market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Exocrine Pancreatic Insufficiency Market Forecast

Some of the key facts of the Exocrine Pancreatic Insufficiency Market Report:

• The Exocrine Pancreatic Insufficiency (EPI) market is projected to experience substantial growth with a notable CAGR over the study period (2020–2034).

• The market is expected to expand further during the forecast period (2024–2034), driven by the rising prevalence of EPI. In 2023, the United States reported the highest number of EPI cases among the seven major markets (7MM), and this trend is anticipated to continue throughout the forecast period.

• Among the primary causes of EPI, Type 2 diabetes mellitus accounted for the largest share of cases across the 7MM. Other significant contributing factors include acute pancreatitis (mild to severe), chronic pancreatitis, cystic fibrosis, and unresectable pancreatic cancer. In the U.S., these conditions remain the leading drivers of EPI incidence.

• Key Companies in the EPI market include AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others.

• Major Therapies under development or currently available include PERTZYE, CREON, FW-EPI (adrulipase), ANG003, among others.

• Overall, the EPI market is expected to grow significantly due to increasing disease prevalence, heightened awareness, and the introduction of innovative, multi-stage pipeline therapies, which are poised to transform the market landscape over the coming decade.

Exocrine Pancreatic Insufficiency Overview

Exocrine pancreatic insufficiency (EPI) arises when the pancreas does not produce sufficient digestive enzymes, impairing the small intestine's ability to properly digest food. This can result in complications such as malnutrition, decreased bone density, and growth delays in children. Common symptoms include bloating, abdominal pain or cramps, and diarrhea. EPI may develop due to underlying conditions such as pancreatitis, cystic fibrosis, pancreatic cancer, or following surgical procedures involving the pancreas or upper gastrointestinal tract.

The diagnosis of EPI involves a comprehensive evaluation by a healthcare professional. It generally starts with a physical examination to identify symptoms indicative of pancreatic insufficiency. To confirm the condition, specific diagnostic tests are performed, including the stool elastase test to measure enzyme levels, blood tests to evaluate pancreatic enzyme function, and pancreatic function assessments such as the secretin stimulation test or direct pancreatic function test to gauge overall pancreatic activity. These diagnostic approaches enable accurate identification of EPI and support the development of an effective treatment strategy.

Get a Free sample for the Exocrine Pancreatic Insufficiency Market Forecast , Size & Share Analysis Report

Exocrine Pancreatic Insufficiency Epidemiology

The epidemiology section offers a comprehensive overview of historical, current, and projected trends in the seven major markets (7MM) from 2020 to 2034. It examines the factors driving both present and future trends by analyzing data from multiple studies and insights from key opinion leaders. Additionally, this section presents a detailed assessment of the diagnosed patient population and outlines anticipated epidemiological developments over the forecast period.

Exocrine Pancreatic Insufficiency Epidemiology Segmentation:

The Exocrine Pancreatic Insufficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Diagnosed Prevalence of Exocrine Pancreatic Insufficiency in Adults

• Diagnosed Prevalence of Exocrine Pancreatic Insufficiency in Pediatrics

• Diagnosed Prevalence of Exocrine Pancreatic Insufficiency by Types

• Diagnosed Prevalence of Exocrine Pancreatic Insufficiency by Location

• Diagnosed Prevalence of Exocrine Pancreatic Insufficiency by Severity

Download the report to understand which factors are driving Exocrine Pancreatic Insufficiency epidemiology trends

Exocrine Pancreatic Insufficiency Marketed Drugs

• PERTZYE: Digestive Care

• CREON: Solvay Pharmaceuticals

Exocrine Pancreatic Insufficiency Emerging Drugs

• FW-EPI (adrulipase): First Wave Biopharma

• ANG003: Anagram Therapeutics

Exocrine Pancreatic Insufficiency Therapies: PERTZYE, CREON, FW-EPI (adrulipase), ANG003, and others

Exocrine Pancreatic Insufficiency Key Companies: AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others

Discover more about therapies set to grab major Exocrine Pancreatic Insufficiency market share @ Exocrine Pancreatic Insufficiency Treatment Landscape

Exocrine Pancreatic Insufficiency Market Outlook

The treatment approach for exocrine pancreatic insufficiency (EPI) primarily involves pancreatic enzyme replacement therapy (PERT), lifestyle modifications (such as reducing fatty food intake, limiting alcohol, quitting smoking, and maintaining a balanced diet), and supplementation of fat-soluble vitamins A, D, E, and K. PERT serves as the first-line therapy and is commonly prescribed to patients. The enzyme formulations used in PERT are derived from porcine pancreas and include all three essential pancreatic enzymes-amylase, protease, and lipase-with lipase being the most critical for therapeutic effect.

Pharmacological therapy is the mainstay of EPI management and is typically administered as monotherapy, with different products not considered interchangeable. Several FDA-approved pancreatic enzyme products (PEPs) are available for treating maldigestion in patients with insufficient pancreatic enzyme production, including CREON, PANCREAZE, PERTZYE, VIOKACE, and ZENPEP. In addition, pain management medications may be required for certain patients.

Scope of the Exocrine Pancreatic Insufficiency Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Exocrine Pancreatic Insufficiency Companies: AbbVie, Nestle, Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc., Chiesi Farmaceutici, and others

• Key Exocrine Pancreatic Insufficiency Therapies: PERTZYE, CREON, FW-EPI (adrulipase), ANG003, and others

• Exocrine Pancreatic Insufficiency Therapeutic Assessment: Exocrine Pancreatic Insufficiency current marketed and Exocrine Pancreatic Insufficiency emerging therapies

• Exocrine Pancreatic Insufficiency Market Dynamics: Exocrine Pancreatic Insufficiency market drivers and Exocrine Pancreatic Insufficiency market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Exocrine Pancreatic Insufficiency Unmet Needs, KOL's views, Analyst's views, Exocrine Pancreatic Insufficiency Market Access and Reimbursement

To know more about Exocrine Pancreatic Insufficiency companies working in the treatment market, visit @ Exocrine Pancreatic Insufficiency Clinical Trials and Therapeutic Assessment

Table of Contents

1. Exocrine Pancreatic Insufficiency Market Report Introduction

2. Executive Summary for Exocrine Pancreatic Insufficiency

3. SWOT analysis of Exocrine Pancreatic Insufficiency

4. Exocrine Pancreatic Insufficiency Patient Share (%) Overview at a Glance

5. Exocrine Pancreatic Insufficiency Market Overview at a Glance

6. Exocrine Pancreatic Insufficiency Disease Background and Overview

7. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Exocrine Pancreatic Insufficiency

9. Exocrine Pancreatic Insufficiency Current Treatment and Medical Practices

10. Exocrine Pancreatic Insufficiency Unmet Needs

11. Exocrine Pancreatic Insufficiency Emerging Therapies

12. Exocrine Pancreatic Insufficiency Market Outlook

13. Country-Wise Exocrine Pancreatic Insufficiency Market Analysis (2020–2034)

14. Exocrine Pancreatic Insufficiency Market Access and Reimbursement of Therapies

15. Exocrine Pancreatic Insufficiency Market Drivers

16. Exocrine Pancreatic Insufficiency Market Barriers

17. Exocrine Pancreatic Insufficiency Appendix

18. Exocrine Pancreatic Insufficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Exocrine Pancreatic Insufficiency Pipeline

"Exocrine Pancreatic Insufficiency Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Exocrine Pancreatic Insufficiency market. A detailed picture of the Exocrine Pancreatic Insufficiency pipeline landscape is provided, which includes the disease overview and Exocrine Pancreatic Insufficiency treatment guidelines.

Exocrine Pancreatic Insufficiency Epidemiology

DelveInsight's 'Exocrine Pancreatic Insufficiency Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Exocrine Pancreatic Insufficiency epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

MENAFN08102025003238003268ID1110170261